Study vs BEE
Price, ratings, monetisation and update history for both apps, side by side — with what reviewers say about each.
Study
Read full descriptionHide full description
这是一个由葛兰素史克(上海)医药研发公司(GSK)开发的一款致力于GSK临床试验的应用。它可以方便临床试验中的资料查看,反馈收集以及发送通知
BEE
This tool assists clinical trial staff in calculating and validating Keratopathy Visual Acuity (KVA) grades for patients. It serves as a calculator for eye exam assessments within specific clinical study agreements.
- KVA grade calculation
- Manual calculation validation
- User-friendly interface
- Clinical trial support tool
- Eye exam assessment
Read full descriptionHide full description
The purpose of the Belamaf (belantamab mafodotin) Eye Exam (BEE) App is to provide a user-friendly calculator-like tool where investigator or site support staff participating in Belamaf Clinical trials can easily assess the Keratopathy Visual Acuity (KVA) grade or validate manual calculation of the KVA grade for their patient's eye exam. Disclaimer: Use of the BEE App is intended for investigators or site support staff trained in use of this App for purpose(s) defined in belantamab mafodotin clinical study agreements or documents. This App is NOT intended for commercial use.
Screenshots
Verdict
The clearest difference is ads: BEE at none against Study's shown. Study's advantage is update cadence (every 3 months vs every 21 months) and iOS requirement (12.1 vs 14.0). On price, in-app purchases and device support there is nothing between them.
Scored on Price · Rating · Positive reviews · Number of ratings · Update frequency · Ads · In-app purchases · Monetization · Best chart rank · Devices · Requires iOS
Both are free to download. Neither carries in-app purchases, so what you see is what you pay.
Study ships an update every 3 months, BEE every 21 months. The most recent releases landed on November 11, 2026 and November 3, 2026 respectively.
| Parameter | Study | BEE |
|---|---|---|
| Price | Free | Free |
| Rating | — | 5.0 (4 ratings) — better |
| Number of ratings | — | 4 — better |
| Update frequency | Every 3 months — better | Every 21 months |
| Ads | Yes | No — better |
| In-app purchases | No | No |
| Monetization | — | Free |
| Devices | iPhone, iPod | iPhone, iPad, iPod — better |
| Requires iOS | 12.1 — better | 14.0 |
| Further details — not scored | ||
| Size | 46 MB | 4 MB |
| Age rating | 17+ | 4+ |
| Developer | GlaxoSmithKline (Shanghai) Pharmaceutical R&D Co., Ltd. | GlaxoSmithKline PLC |
In-app purchases
Study
No in-app purchases
BEE
No in-app purchases







